Medpace Holdings (MEDP) opened Q2 2026 with total revenue of US$707.3 million and basic EPS of US$4.31, while trailing twelve month figures show revenue of US$2.8 billion and EPS of US$17.39 alongside 17.5% earnings growth and 21.2% annual earnings compounding over five years. The company has seen revenue move from US$2.2 billion and EPS of US$13.83 on a trailing basis in Q2 2025 to the latest trailing tallies, with earnings growth of 8.5% and revenue growth of 6.7% flagged in forecasts, against a trailing net profit margin of 17.7% versus 18.7% a year earlier. This sets up a results snapshot where investors will focus closely on how margins are holding up around that profile.

See our full analysis for Medpace Holdings.

With the headline numbers on the table, the next step is to line these results up against the most widely held narratives around Medpace Holdings to see which stories the data supports and which ones start to look stretched.

Medpace margins ease from 18.7% to 17.7%

• On a trailing basis, Medpace Holdings is converting US$2.8b of revenue into US$491.5 million of net income, which works out to a 17.7% net margin compared with 18.7% a year earlier.
• Bears argue that margin pressure could become a bigger issue as reimbursable pass through revenue and faster burning studies fade, yet the current 17.7% margin and US$491.5 million of trailing net income show:
  • Backlog concerns in the cautious narrative, including a reported year over year backlog decline of about 2%, are not yet reflected in trailing net income, which is higher than the US$418.3 million recorded on a trailing basis a year earlier.
  • Even with a modest margin step down from 18.7% to 17.7%, the business is still earning a high level of profit relative to its US$2.8b revenue base, which partly challenges the idea that profitability is already under severe strain.

Medpace EPS growth vs slower forecasts

• Trailing twelve month basic EPS sits at US$17.39, up from US$13.83 a year earlier, while analysts are forecasting earnings growth of about 8.5% per year and revenue growth of 6.7% per year from here.
• The bullish narrative leans on the idea of revenue compounding well above consensus, yet the current numbers and forecasts together paint a more mixed picture:
  • History supports the bulls, as five year earnings have compounded at 21.2% per year and trailing earnings grew 17.5% over the last year, which is stronger than the 8.5% growth rate being modeled going forward.
  • Forecast growth of 6.7% for revenue and 8.5% for earnings is below the broader US market expectations cited, so the present trajectory does not yet match the more aggressive assumptions in the optimistic storyline.

On these numbers, bulls are watching whether Medpace can keep earnings closer to the 17.5% trailing growth rate rather than drift toward the 8.5% analysts have penciled in, and the full bullish case sets out what that path could look like in practice 🐂 Medpace Holdings Bull Case

Medpace valuation sits below DCF fair value

• At a share price of US$605.82, Medpace trades on a 34.4x P/E versus a 69.1x peer average and 36.3x for the Global Life Sciences industry, and sits below an indicated DCF fair value of about US$662.82.
• Critics highlight that even with this P/E discount, the stock could still be pricing in more growth than the cautious narrative is comfortable with:
  • The bearish view points to risks such as a reported 1.8% year over year backlog decline and potential revenue slowdown, yet the current multiple of 34.4x is already below both the peer average and the industry average, which limits how far valuation can be stretched relative to those groups in that narrative.
  • Analysts are using a central price target of US$489.42, which is below the current share price, so anyone leaning on the bearish story has to weigh that lower target against the fact that the DCF fair value of about US$662.82 is still higher than where the stock is trading today.

For readers weighing that cautious view, it is worth seeing how the more skeptical narrative frames backlog, margins, and funding risk against today’s valuation setup 🐻 Medpace Holdings Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Medpace Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the Medpace Holdings story still feels finely balanced to you, now is a good time to check the details yourself and move quickly while opinions are forming. To see why some investors are focusing on the more optimistic angles, review the 3 key rewards.

See What Else Is Out There

Medpace Holdings is facing questions around easing margins, slower forecast growth compared to its history, and a valuation that some investors view as demanding.

If those pressure points leave you wanting a wider set of ideas, now is a good time to look at companies that screen as potentially better value through the 38 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.